Nucleic Acid Testing Accelerates, BGI Genomics Shares up 92.95% This Year
BGI Genomics (300676:SZ) rose nearly 8% intraday to a record high of CNY 136.31 on June 11. It closed at CNY 132.56. Based on the closing price, the stock price of the company has risen 92.95% this year. The novel coronavirus test kit from BGI is one of the first products approved for marketing in China. On January 26, two of the company's test kits and analysis software, as well as its DNBSEQ-T7 sequencing system, were approved simultaneously. The emergency approval process of the State Drug Administration (SDA). Since then, the novel coronavirus nucleic acid test products of BGI have been approved by the European Union, the United States, Japan, Australia and other countries or regions, becoming the most proven products overseas.